Investment Rating - Maintain BUY rating with a revised target price of HKD 6.21 (down from HKD 8.51) [2][3] Core Views - CSPC Pharmaceutical reported moderate growth in 1H24, with total revenue increasing by 1.3% YoY to RMB 16.28 billion and net profit attributable to shareholders rising by 1.8% YoY to RMB 3.02 billion [1] - The company faces pricing pressure on key products like Jinyouli and Duomeisu due to the "3+N" provincial volume-based procurement policy, leading to significant price reductions [1] - New product sales targets for FY24 have been revised downward from RMB 3 billion to RMB 2 billion due to delays in hospital listings caused by regulatory challenges [2] - The company expects four assets to enter the National Reimbursement Drug List (NRDL) by the end of 2024, which could offset the decline in sales of oncology products [2] Financial Performance - In 2Q24, CSPC's revenue declined by 8.1% YoY and 20.8% QoQ to RMB 5.99 billion, while net profit attributable to shareholders increased by 42.2% YoY and 35.7% QoQ to RMB 2.19 billion [1] - Gross margin improved to 71.6% in 1H24, up from 69.9% in 1H23, driven by a higher proportion of revenue from finished drugs [1] - R&D expenses in 2Q24 reached RMB 1.37 billion, up 17.4% QoQ [1] - Sales of oncology, cardiovascular, and respiratory products declined by 30.6%, 27.0%, and 23.1% YoY, respectively, in 2Q24 [1] Product Performance - Jinyouli's price was reduced by 58.4% to RMB 666 per 3mg, while Duomeisu (10mg) and Duomeisu (20mg) saw price reductions of 10.0% and 21.8%, respectively [1] - NBP (Neurology Business Platform) performed well in 1H24, with sales of neurological products increasing by 4.2% YoY to RMB 2.53 billion, driven by strong growth in retail pharmacy channels [1] Future Outlook - CSPC expects new product sales to grow in 2H24 and 2025, with products like Mingfule (rhTNK-tPA), Duoni (Enoxaparin Liposome), and Anfulike (Amoxicillin B) contributing to growth [2] - The company anticipates that Mingfule will gain additional sales potential with the inclusion of acute ischemic stroke in the NRDL negotiations by the end of 2024 [2] - Revenue and net profit attributable to shareholders are forecasted to grow by 1.3% and 0.5% in FY24, and by 1.3% and -1.5% in FY25, respectively [2] Valuation - The DCF-based valuation has been revised downward to HKD 6.21, with a WACC of 11.78% and a terminal growth rate of 2.0% [2] - Sensitivity analysis shows a target price range of HKD 5.59 to HKD 7.13 based on varying WACC and terminal growth rate assumptions [6]

23 Aug 2024 CMB International Global Markets | Equity Research | Company Update WuXi Biologics (2269 HK) Robust performance in a challenging environment Wuxi Bio reported 1H24 revenue of RMB8.57bn, up 1.0% YoY, and adjusted attributable net income of RMB2.25bn, down 20.7% YoY. 1H24 revenue and adjusted attributable net income accounted for 47.9% and 44.5% of our full-year forecasts, moderately higher than the historical levels. If excluding COVID revenue, total revenue in 1H24 would increase by 7.7% YoY, wh ...

23 Aug 2024 CMB International Global Markets | Equity Research | Company Update Onewo (2602 HK) | --- | --- | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

23 Aug 2024 CMB International Global Markets | Equity Research | Company Update CSPC Pharmaceutical (1093 HK) HK) Legacy products faced pricing pressures Moderate growth in 1H24. In 1H24, CSPC's total revenue increased by 1.3% YoY to RMB16.28bn and the attributable net profit increased by 1.8% YoY to RMB3.02bn, accounting for 46% and 45% of our previous full-year estimates. For 2Q24, the total revenue was RMB5.99bn (-8.1% YoY, -20.8% QoQ) and the attributable net profit was RMB2.19bn (+42.2% YoY, +35.7% QoQ ...

2024 年 8 月 23 日 招银国际环球市场 | 睿智投资 | 公司更新 韦尔股份 (603501 CH) 1H24 业绩稳健，CIS 业务持续复苏 韦尔股份公布了 2024 年上半年业绩。上半年收入同比增长 36.5%至 120 亿元人 民币，净利润较去年同期的低基数（1.53 亿元人民币）同比增长 790%至 13.7 亿元人民币。按季度来看，公司二季度收入为 64 亿元人民币（同比增长 42.5%，环比增长 14.2%，符合彭博一致预期），创历史新高。二季度净利润为 8.09 亿元人民币，环比增长 45.1%（2023 年二季度为净亏损）。公司二季度毛 利率提升至 30.2%（上季度和去年同期分别为 27.9%、17.3%）。毛利率的改善 表明公司业务正在稳步恢复。同时，得益于成本结构的持续优化，二季度净利润 率上升至 12.6%（上季度和去年同期分别为 9.9%、-1%）。管理层认为，公司 的强劲业绩主要得益于：1）2024 年上半年消费市场的逐步复苏；2）公司产品 在高端智能手机市场（尤其是国内安卓机型）上的份额提升、以及汽车 CIS 销 售的持续增长；3）产品组合优化推动毛利率改善。维持 "买 ...

23 Aug 2024 CMB 国际全球市场 | 股票研究 | 公司更新 AAC Tech （ 2018 香港 ）骑上新的升级周期 ； 升级购买 (上一个 TP HK$37.80 HK$22.44) 21.0% 我们将 AAC 升级为基于 SOTP 的 TP 为 37.8 港元 （ 25 财年市盈率为 19.6 倍 ） ， 因为我们相信声学 / 光学 / 触觉和即将到来的 AI 的规范升级 智能手机周期将推动收益增长至 FY25 / 26E 。 AAC 的 1H24 营收 / 净利润同比增长 22% / 257% 超市场预期 ， 。 得益于强劲的利润率恢复 (同比 + 7.4 个百分点 / + 2.3 个百分点) ， 更好 声学 / 光学 / PM 和 PSS 整合的产品组合。对于 FY24E ， 管理层。 在 GPM HoH 扩张的推动下 ， 销售额同比增长 15% （ 不包括 PSS ） 通过 ： 1 ） 光学 ： 更好的 HSL / HCM ASP / 出货量 ， 并将 GPM 提高到 4Q24E ， 2 ） 声学 ： SLS / Combo 产品渗透 ， 3 ） 触觉 / 外壳 / 铰链 ： 高 最终 ...

Investment Rating - The report maintains a BUY rating for Baidu with a target price of US$180.50, down from the previous target of US$183.00, indicating an upside potential of 101.1% from the current price of US$89.74 [3]. Core Insights - Baidu's 2Q24 revenue was RMB33.9 billion, a slight decline of 0.4% year-over-year, aligning with Bloomberg consensus. Non-GAAP net income was RMB7.4 billion, exceeding consensus by 9% due to effective control over sales and marketing expenses [2]. - The company is focusing on enhancing user experience through Gen-AI generated results, prioritizing this over short-term monetization, which may temporarily hinder ad revenue growth but is expected to improve long-term monetization prospects [2][10]. - Non-ad revenue grew by 10% year-over-year to RMB7.5 billion, now accounting for 28.2% of Baidu Core revenue, driven by AI-related GPU cloud revenue and cross-selling of CPU cloud services [2]. Financial Performance - In 2Q24, Baidu Core's online ads revenue was RMB19.2 billion, down 2.2% year-over-year, but slightly better than consensus expectations. The company anticipates a further decline in ad revenue growth in the near term, projecting a 3.4% year-over-year decline to RMB19.0 billion in 3Q24E [2][7]. - Baidu Core's gross profit margin (GPM) was 59.4% in 2Q24, down 1.1 percentage points year-over-year, while non-GAAP operating profit margin (OPM) improved to 26.1%, exceeding consensus by 1.4 percentage points due to stringent cost control [2][7]. Valuation and Forecast - The SOTP-based target price of US$180.5 reflects a valuation of US$71.6 for Baidu Core, US$1.8 for Apollo ASD, US$32.2 for Baidu Cloud, and US$64.1 in net cash. The valuation for iQIYI and other investments is set at US$10.8 [10][11]. - Revenue forecasts for FY24E, FY25E, and FY26E are RMB135.8 billion, RMB146.9 billion, and RMB157.9 billion respectively, with adjusted net profit estimates of RMB27.96 billion, RMB28.72 billion, and RMB31.94 billion [6][9].

23 Aug 2024 CMB International Global Markets | Equity Research | Company Update AAC Tech (2018 HK) Riding on new upgrade cycle; Upgrade to BUY We upgrade AAC to BUY with SOTP-based TP of HK$37.8 (19.6x FY25E P/E), as we believe spec upgrade in acoustics/optics/haptics and upcoming AI smartphone cycle will boost earnings growth into FY25/26E. AAC's 1H24 revenue/net profit growth of 22%/257% YoY is ahead of market expectations, thanks to stronger margin recovery (+7.4 ppts YoY/+2.3 ppts HoH), better product m ...

Investment Rating - The report maintains a "Buy" rating for Willsemi, with a target price adjusted to RMB 115.39, based on a 2024E price-to-earnings ratio of 40.7 times [1][2]. Core Insights - Willsemi reported a robust performance in 1H24, with revenue increasing by 36.5% year-on-year to RMB 12 billion and net profit soaring by 790% to RMB 13.7 billion, attributed to improved consumer sentiment and growth in high-end smartphone and automotive CIS markets [1][2]. - The company's CIS sales in mobile, automotive, IoT, and medical sectors showed strong growth, with year-on-year increases of 78.5%, 53.0%, 77.8%, and 41.6% respectively, despite a decline in security and notebook sectors [1][2]. - The report anticipates a 15% growth in CIS sales for the second half of 2024, projecting an annual growth rate of 29% for the year [1]. Financial Summary - Revenue is projected to reach RMB 26.1 billion in FY24, with a year-on-year growth rate of 24.3%. The gross profit margin is expected to be 29.7% [3][9]. - Net profit for FY24 is estimated at RMB 3.37 billion, reflecting a significant year-on-year increase of 507.2% [3][9]. - The report indicates a gradual recovery in the touch/display business, with a forecasted return to growth starting in 2025 due to the introduction of low-power and automotive-grade products [2][3]. Market Performance - Willsemi's sales in the CIS segment for the first half of 2024 continued to show strong momentum, with a 49.8% year-on-year increase in sales to the CIS market [1][2]. - The report highlights the company's leading position in the market and ongoing market share growth, despite a challenging overall market environment [2][3].

22 Aug 2024 CMB International Global Markets | Equity Research | Company Update Willsemi (603501 CH) Solid 1H24 results with continued recovery in CIS business Willsemi released 1H24 results. Revenue increased by 36.5% YoY to RMB12bn, while net profit grew 790% YoY from a low base in 1H23 (RMB153mn) to RMB1.37bn in 1H24. On a quarterly basis, the company achieved a record revenue at RMB6.4bn in 2Q24 (42.5% YoY/14.2% QoQ, in line with consensus estimate). Q2 net profit was RMB809mn, up 45.1% QoQ (2Q23 was in ...